Latest Expert Opinions

Signal
Opinion
Expert
TOP PICK
TOP PICK
May 6, 2019
It's entering seasonal strength, based on nice moves in the past two years. Biotech has been a hot potato in American politics, but is on the leading edge that will change society. These stocks are undervalued.
Show full opinionHide full opinion
It's entering seasonal strength, based on nice moves in the past two years. Biotech has been a hot potato in American politics, but is on the leading edge that will change society. These stocks are undervalued.
TOP PICK
TOP PICK
May 6, 2019
Trades at an enterprise value to adjusted cash flow at 4.2x vs. peers at 6x, so ERF has been really beat up. Showing a nice uptrend in the past two years. Had a good, sustainable buyback program happening. Great cash flow. It's entering seasonality from late-April to August. (Analysts’ price target is $17.36)
Show full opinionHide full opinion
Trades at an enterprise value to adjusted cash flow at 4.2x vs. peers at 6x, so ERF has been really beat up. Showing a nice uptrend in the past two years. Had a good, sustainable buyback program happening. Great cash flow. It's entering seasonality from late-April to August. (Analysts’ price target is $17.36)
TOP PICK
TOP PICK
May 6, 2019
Set up now for good seasonality. The premium company in this space. It's volatile, though rangebound over the past 30 months. Excellent balance sheet. The US dollar is a tailwind. For the past 10 summers, FNV has outperformed the market by 9%. (Analysts’ price target is $110.12)
Show full opinionHide full opinion
Set up now for good seasonality. The premium company in this space. It's volatile, though rangebound over the past 30 months. Excellent balance sheet. The US dollar is a tailwind. For the past 10 summers, FNV has outperformed the market by 9%. (Analysts’ price target is $110.12)